The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Oncosec finally announced an update from their early stage triple negative breast cancer trial. This data was presented last Thursday at the San Antonio Breast Conference. For … Continue Reading
Read nowInsights - There is a misconception that Bellus is lacking catalysts following their strong Phase 1 data released last week (read here). We don’t necessarily agree with the … Continue Reading
Read nowInsights - We are looking forward to December catalysts and watching two companies with near term readouts that we think the market is under appreciating. Both present … Continue Reading
Read nowInsights - Bellus had a call this morning (listen here) to discuss their Phase 1 data, released yesterday after market. As reported yesterday, at their anticipated therapeutic doses … Continue Reading
Read nowInsights - Amarin released detailed REDUCE-IT data this past Saturday and results were mixed. Although the Vascepa active arm showed strong data, the placebo arm used mineral oil, which … Continue Reading
Read nowInsights - Oncosec (ONCS) reported data from PICES combination trial with Keytruda this morning and came below expectations. ONCS stock is down more than 50% on the data, which … Continue Reading
Read nowInsights - Bellus is expected to report Phase 1 data, which will include taste, sometime in late November – early December. Below we analyze Merck’s Phase 2b … Continue Reading
Read now
